Healthcare Professionals

Continuing Education

Enrol in RACGP accredited educational activities worth 40 Category 1 CPD points.

About Emphysema

Emphysema – a severe form of Chronic Obstructive Pulmonary Disease (COPD) – is a progressive disease that traps air in the air sacs in the lungs (alveoli) and causes hyperinflation, which makes it difficult to expel air from the lungs.

Zephyr® Valve Procedure

Zephyr Endobronchial Valve procedure overview.

Product Overview

The Pulmonx portfolio of diagnostics and therapeutics for emphysema enables physicians to successfully predict outcomes and provide optimal treatment for each individual patient.

Clinical Evidence

Zephyr Endobronchial Valves demonstrated to significantly improve breathing, mobility and quality of life for emphysema patients.

Patient Selection

Selection criteria for the Zephyr Valve therapy include patients who:

  • Have a history of smoking.
  • Are symptomatic and experience persistent shortness of breath, despite optimal medication (inhalers).
  • Have a FEV1 of <59% on a spirometry test.

Referral Centres

Refer to a Zephyr Endobronchial Valve Treating Physician at one of our partnering hospitals. Your patient will undergo further lung function assessments to determine suitability for Zephyr Valves.

Resource Library

Download the latest referral centre lists, FAST TRACK referral forms, patient information guides and more.

Media Releases

Keep up to date with the latest media releases from Pulmonx for Healthcare Professionals.

FAQs

What is the Zephyr Endobronchial Valve?

The Zephyr Valve is a tiny valve designed to reduce hyperinflation. The valve blocks airflow to the diseased region of the lung to allow the healthy region to expand and function more efficiently, resulting in improved breathing and quality of life.

Contact Us

Get in touch with us for further information or to request to speak with your local Pulmonx representative.

HEALTHCARE PROFESSIONAL USE ONLY 

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, haemoptysis, pneumonia, dyspnoea and, in rare cases, death.